- Home
- CLCO vs INBX Comparison
CLCO vs INBX Comparison
Compare CLCO & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLCO
- INBX
- Stock Information
- Founded
- CLCO 2018
- INBX 2010
- Country
- CLCO United Kingdom
- INBX United States
- Employees
- CLCO N/A
- INBX N/A
- Industry
- CLCO
- INBX Biotechnology: Pharmaceutical Preparations
- Sector
- CLCO
- INBX Health Care
- Exchange
- CLCO Nasdaq
- INBX Nasdaq
- Market Cap
- CLCO 360.2M
- INBX 341.2M
- IPO Year
- CLCO N/A
- INBX 2020
- Fundamental
- Price
- CLCO $7.44
- INBX $23.33
- Analyst Decision
- CLCO
- INBX Hold
- Analyst Count
- CLCO 0
- INBX 1
- Target Price
- CLCO N/A
- INBX N/A
- AVG Volume (30 Days)
- CLCO 68.4K
- INBX 101.4K
- Earning Date
- CLCO 08-28-2025
- INBX 08-13-2025
- Dividend Yield
- CLCO 8.12%
- INBX N/A
- EPS Growth
- CLCO N/A
- INBX N/A
- EPS
- CLCO 1.31
- INBX N/A
- Revenue
- CLCO $320,759,000.00
- INBX $1,400,000.00
- Revenue This Year
- CLCO $2.10
- INBX N/A
- Revenue Next Year
- CLCO N/A
- INBX N/A
- P/E Ratio
- CLCO $5.63
- INBX N/A
- Revenue Growth
- CLCO N/A
- INBX N/A
- 52 Week Low
- CLCO $4.51
- INBX $10.81
- 52 Week High
- CLCO $12.41
- INBX $25.29
- Technical
- Relative Strength Index (RSI)
- CLCO 58.00
- INBX 61.05
- Support Level
- CLCO $7.01
- INBX $20.55
- Resistance Level
- CLCO $7.65
- INBX $24.48
- Average True Range (ATR)
- CLCO 0.28
- INBX 1.49
- MACD
- CLCO 0.01
- INBX -0.10
- Stochastic Oscillator
- CLCO 69.57
- INBX 58.65
About CLCO Cool Company Ltd.
Cool Co Ltd is a LNG shipping company. The company is engaged in the acquisition, ownership, operation and chartering of liquefied natural gas (LNG) carriers (LNGCs), and the operation of third party fleets under management agreements. The company manages its business through a single operating and reporting segment, the LNG carrier market.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.